Advertisement
MIST vs TSHA
Which Stock Would AI Choose? Milestone Pharmaceuticals (MIST) vs. Taysha Gene Therapies (TSHA) Stock Comparison
Key Takeaways
- MIST is a commercial-stage biopharmaceutical company launching CARDAMYST, an approved nasal spray for PSVT (paroxysmal supraventricular tachycardia), while TSHA is a pre-revenue, clinical-stage gene therapy developer.
- MIST has shown early commercial traction, with formulary coverage expanding to roughly half of commercially insured lives and accelerating prescription growth in recent weeks.
- TSHA is approaching pivotal milestones for its lead asset TSHA-102, including completion of dosing in its REVEAL and ASPIRE trials and preparation for a potential BLA (Biologics License Application) submission.
- Both names carry elevated volatility, but MIST currently offers more visible near-term revenue and multiple catalysts, whereas TSHA remains tied to binary clinical and regulatory outcomes.
- Tickeron AI Verdict: Based on trend consistency, relative stability, and nearer-term catalysts, the AI framework currently leans toward MIST over TSHA.
- For deeper coverage, explore MIST Major News and MIST Today's Price Move, as well as TSHA Major News and TSHA Today's Price Move.
- To see how automated strategies are positioning across the market, explore Trending AI Robots.
Introduction
Both MIST and TSHA operate in the biotechnology sector, yet they sit at very different stages of the corporate life cycle. Milestone Pharmaceuticals has transitioned to a commercial-stage company with a newly launched product, while Taysha Gene Therapies remains in late-stage clinical development with no product revenue. This stock comparison is most relevant to growth-oriented traders and investors weighing a company generating early commercial traction against one positioned ahead of a high-impact regulatory catalyst. The contrast in business models, risk profiles, and market positioning makes these two tickers a useful case study in relative performance and sentiment shifts.
MIST Overview and Recent Performance
MIST, or Milestone Pharmaceuticals, is a biopharmaceutical company focused on innovative cardiovascular medicines. Its lead product, CARDAMYST (etripamil) nasal spray, is approved for acute episodes of PSVT, a condition marked by sudden rapid heartbeats. Recent market activity has been shaped by the early stages of this product launch. Management has reported steady month-over-month prescription growth, and formulary coverage has expanded from roughly 25% to more than half of commercially insured lives following payer wins, including Express Scripts and UnitedHealthcare-related plans.
Beyond the launch, Milestone has advanced its pipeline by initiating a Phase III trial (ReVeRA-301) evaluating etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR). It also secured its first regulatory approval outside the United States, in China, which triggered a milestone payment. These catalysts, combined with a cash position expected to fund operations into the second half of 2027, have contributed to a more constructive sentiment profile, even as the company continues to report widening net losses during the investment-heavy launch phase.
TSHA Overview and Recent Performance
TSHA, or Taysha Gene Therapies, is a clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead candidate, TSHA-102, targets Rett syndrome, a rare neurodevelopmental disorder. Recent market activity has centered on clinical and regulatory progress rather than commercial results. The company completed dosing in both its REVEAL pivotal and ASPIRE trials and presented longer-term data suggesting durable, deepening functional gains in treated patients.
Taysha has also advanced manufacturing readiness by initiating a BLA-enabling process performance qualification campaign and expanding its partnership with Catalent as a commercial manufacturing partner. A follow-on financing strengthened the balance sheet, with cash expected to fund operations into the second half of 2028. Because the company remains pre-revenue, its stock tends to move on clinical data readouts and FDA (Food and Drug Administration) interactions, creating a binary risk-and-reward profile relative to commercial-stage peers.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots from a broader universe of hundreds of automated strategies that trade thousands of tickers. Each bot operates with its own trading style, strategy, timeframe, performance record, and set of securities, so no single approach fits every market condition. The robots featured in this section are selected for their suitability to current market environments, offering traders a way to observe quantitative, rules-based positioning alongside their own analysis. Whether you are evaluating a commercial-stage launch or a pre-revenue clinical catalyst, reviewing how automated systems are currently trading can add a useful quantitative layer to your research. Explore the Trending AI Robots page to see which strategies are performing well right now.
Head-to-Head Comparison
The clearest contrast between these two companies is stage of development. MIST is generating revenue, albeit modest, and its growth drivers are tied to commercial execution, payer coverage expansion, and pipeline advancement. TSHA has no product revenue, and its valuation is driven by the probability of clinical and regulatory success for TSHA-102.
Risk profiles also differ. Milestone faces launch execution risk, reimbursement negotiation, and the normal uncertainty of expanding a commercial footprint. Taysha faces binary event risk around its pivotal data and BLA pathway, where a single readout can move the stock sharply in either direction. On market positioning, MIST offers more granular, near-term operating metrics for investors to track, while TSHA offers a larger potential addressable market but with longer, more uncertain timelines. Sector exposure is broadly similar, as both are U.S.-listed biotechnology companies sensitive to interest rates, sentiment toward small-cap healthcare, and regulatory headlines.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and the proximity and clarity of catalysts, Tickeron's AI framework would likely favor MIST in the current environment. Milestone offers a commercialized product, expanding payer coverage, and multiple catalysts across both launch execution and pipeline development, which tend to produce a steadier, more measurable trend. Taysha's TSHA-102 program holds substantial long-term potential, but its nearer-term trajectory remains dependent on binary clinical and regulatory outcomes that introduce greater volatility. This assessment reflects a probabilistic comparison of relative positioning rather than a definitive forecast, and the balance could shift as new data emerges for either company.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MIST is a Hold and TSHA is a Hold.
MIST in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 23, 2026
MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 37 cases where MIST's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MIST's RSI Indicator exited the oversold zone, 24 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for MIST just turned positive on October 27, 2026. Looking at past instances where MIST's MACD turned positive, the stock continued to rise in 34 of 43 cases over the following month. The odds of a continued upward trend are 79%.
Following a +7.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIST as a result. In 67 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MIST entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.213) is normal, around the industry mean (3.498). P/E Ratio (-1.174) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
TSHA's RSI Oscillator recovers from oversold territory
The RSI Indicator for TSHA moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In 36 of the 36 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on TSHA as a result. In 74 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for TSHA just turned positive on October 21, 2026. Looking at past instances where TSHA's MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.
Following a +6.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where TSHA advanced for three days, in 213 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
TSHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 53 cases where TSHA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The 50-day moving average for TSHA moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TSHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TSHA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.643) is normal, around the industry mean (3.498). P/E Ratio (-10.561) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. TSHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TSHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MIST | TSHA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 22 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 73 Overvalued | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 85 | 63 | |
P/E GROWTH RATING 1..100 | 13 | 19 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TSHA's Valuation (22) in the null industry is somewhat better than the same rating for MIST (73) in the Pharmaceuticals Major industry. This means that TSHA’s stock grew somewhat faster than MIST’s over the last 12 months.
TSHA's Profit vs Risk Rating (100) in the null industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that TSHA’s stock grew similarly to MIST’s over the last 12 months.
TSHA's SMR Rating (98) in the null industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that TSHA’s stock grew similarly to MIST’s over the last 12 months.
TSHA's Price Growth Rating (63) in the null industry is in the same range as MIST (85) in the Pharmaceuticals Major industry. This means that TSHA’s stock grew similarly to MIST’s over the last 12 months.
MIST's P/E Growth Rating (13) in the Pharmaceuticals Major industry is in the same range as TSHA (19) in the null industry. This means that MIST’s stock grew similarly to TSHA’s over the last 12 months.
| MIST | TSHA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 86% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 89% |
| MACD ODDS (%) | 1 day ago 79% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 88% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 83% |
| Advances ODDS (%) | 9 days ago 84% | 4 days ago 82% |
| Declines ODDS (%) | 3 days ago 85% | 11 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MIST’s FA Score shows that 1 FA rating(s) are green while TSHA’s FA Score has 2 green FA rating(s).
- MIST’s FA Score: 1 green, 4 red.
- TSHA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MIST’s TA Score shows that 5 TA indicator(s) are bullish while TSHA’s TA Score has 5 bullish TA indicator(s).
- MIST’s TA Score: 5 bullish, 3 bearish.
- TSHA’s TA Score: 5 bullish, 4 bearish.
Price Growth
MIST (@Biotechnology) experienced а -14.28% price change this week, while TSHA (@Biotechnology) price change was -1.83% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
MIST is expected to report earnings on Nov 13, 2026.
TSHA is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MIST and
Correlation & Price change
A.I.dvisor indicates that over the last year, MIST has been loosely correlated with RCUS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MIST jumps, then RCUS could also see price increases.
| Ticker / NAME | Correlation To MIST | 1D Price Change % | ||
|---|---|---|---|---|
| MIST | 100% | N/A | ||
| RCUS - MIST | 45% Loosely correlated | +0.70% | ||
| TSHA - MIST | 41% Loosely correlated | +0.12% | ||
| RCKT - MIST | 41% Loosely correlated | +1.22% | ||
| DYN - MIST | 40% Loosely correlated | +0.39% | ||
| NAMS - MIST | 40% Loosely correlated | +8.03% | ||
More | ||||
TSHA and
Correlation & Price change
A.I.dvisor indicates that over the last year, TSHA has been loosely correlated with SLDB. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if TSHA jumps, then SLDB could also see price increases.
| Ticker / NAME | Correlation To TSHA | 1D Price Change % | ||
|---|---|---|---|---|
| TSHA | 100% | +0.12% | ||
| SLDB - TSHA | 54% Loosely correlated | +6.00% | ||
| STOK - TSHA | 51% Loosely correlated | +2.02% | ||
| MGTX - TSHA | 51% Loosely correlated | +0.62% | ||
| FDMT - TSHA | 51% Loosely correlated | +4.25% | ||
| KYTX - TSHA | 51% Loosely correlated | +0.79% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QGRO | 115.27 | 1.96 | +1.73% |
| American Century U.S. Quality Growth ETF (QGRO) | |||
| BBHM | 12.21 | 0.17 | +1.45% |
| BBH Select Mid Cap ETF (BBHM) | |||
| PGP | 8.37 | 0.02 | +0.24% |
| PIMCO Global StockPLUS & Income Fund | |||
| LFAW | 167.02 | N/A | N/A |
| LifeX 2060 Longevity Income ETF (LFAW) | |||
| HIBS | 19.80 | -2.03 | -9.30% |
| Direxion Daily S&P 500 High Beta Bear 3X ETF (HIBS) | |||